Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jan 3 2024

Full Issue

Study: Nirsevimab Helps Prevent Hospitalization For Infants With RSV

Read recent pharmaceutical developments in KFF Health News' Prescription Drug Watch roundup.

New England Journal of Medicine: Nirsevimab For Prevention Of Hospitalizations Due To RSV In Infants 

The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract infection when administered in healthy infants are unclear. (Drysdale, et al, 12/28)

CIDRAP: Switch To Oral Antibiotics Occurred For Fewer Than Half Of Eligible Bloodstream Infection Patients 

A study of US patients hospitalized with gram-negative bloodstream infections (GN-BSIs) found that fewer than half of those eligible were transitioned from intravenous (IV) to oral antibiotic therapy. (Dall, 1/2)

CIDRAP: Diagnostic Stewardship Bundle Linked To Reduced Antibiotic Use In Ventilator-Associated Pneumonia 

Implementation of a diagnostic stewardship intervention for suspected pneumonia at a Michigan hospital was associated with a reduction in positive respiratory cultures and broad-spectrum antibiotic use, researchers reported last week in Clinical Microbiology and Infection. (Dall, 1/2)

ScienceDaily: New Method Illuminates Druggable Sites On Proteins 

Scientists develop a new, high-resolution technique for finding potential therapeutic targets on proteins in living cells. The findings could lead to more targeted therapeutics for nearly any human disease. (Scripps Research Institute, 1/2)

CIDRAP: Less Than 5% Of US Preschool Cohort Hospitalized For COVID Were Fully Vaccinated, Study Finds

Only 4.5% of a cohort of pediatric COVID-19 patients admitted to US hospitals during the period of Omicron predominance had completed their primary COVID-19 vaccine series, and 7.0% had started but didn't finish the series, The Pediatric Infectious Disease Journal reports. (Van Beusekom, 12/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF